NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to raise approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants have an exercise price of $1.75 per share and a three-year term, with the closing anticipated on or about May 18, 2026, subject to customary conditions.
This capital infusion is significant for NanoViricides as it continues to develop its lead drug candidate, NV-387, a broad-spectrum antiviral based on host-mimetic nanomedicine technology. NV-387 has received Orphan Drug Designation (ODD) from the U.S. FDA Office of Orphan Products Development, which could provide seven years of market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. The drug is designed to be a first-line treatment for respiratory viral illnesses and has shown effectiveness in lethal animal infection models for Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.
The offering underscores investor confidence in NanoViricides' approach to developing antivirals that viruses and their variants cannot evade. The company's technology platform aims to address the urgent need for broad-spectrum antiviral therapies, particularly in the wake of the COVID-19 pandemic and ongoing threats from emerging viral diseases. The proceeds from this offering are expected to support the continued clinical development of NV-387 and other pipeline candidates.
For more details on the offering, visit https://ibn.fm/Z8Etj. Updates on NanoViricides and its progress can be found in the company's newsroom at https://ibn.fm/NNVC.
